Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study.
Adenovirus Infections, Human
/ drug therapy
Administration, Ophthalmic
Adolescent
Adult
Aged
Child
Conjunctivitis, Viral
/ drug therapy
Cyclosporine
/ therapeutic use
Double-Blind Method
Epithelium, Corneal
/ drug effects
Female
Fluorometholone
/ therapeutic use
Glucocorticoids
/ therapeutic use
Humans
Immunosuppressive Agents
/ therapeutic use
Male
Middle Aged
Ophthalmic Solutions
Prospective Studies
Treatment Outcome
Visual Acuity
/ physiology
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
01 Jun 2021
01 Jun 2021
Historique:
received:
17
05
2020
accepted:
11
09
2020
pubmed:
18
11
2020
medline:
6
11
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
To compare efficiency and tolerance between topical 0.5% cyclosporine A (CSA) and fluorometholone (FML) for subepithelial infiltrates (SEI) complicating epidemic keratoconjunctivitis. We conducted a prospective double-blind randomized study involving 72 eyes with SEI. Thirty-eight eyes were treated with topical FML (FML group) and 34 eyes with CSA 0.5% eye drops (CSA group). Treatment was considered successful in case of SEI reduction and visual acuity improvement. Tolerance was evaluated by Schirmer test value, burning on eye drops instillation, and conjunctival injection. Baseline characteristics of both groups were similar (P > 0.05). After 3 months of the regimen, resolution of SEI was 3 times more observed in the FML group than that in the CSA group (P = 0.026). After 6 months, resolution of SEI was observed in 70% of the FML group and in 47% of the CSA group (P = 0.068). The recurrence of SEI was almost twice higher in the FML group than that in the CSA group (16% vs. 9%). FML was better tolerated during the first 3 months: a higher Schirmer test value (P = 0.0003), less burning on instillation (P = 0.242), and less conjunctival injection (P = 0.003). For the rest of the follow-up period, the 2 groups were comparable in tolerance. No ocular hypertension was noted. Epidemic keratoconjunctivitis can evolve favorably under both FML and CSA. The effect of FML is faster and CSA is more durable with fewer recurrences. Both are safe therapeutic options for long-term control of SEI.
Identifiants
pubmed: 33201059
pii: 00003226-202106000-00010
doi: 10.1097/ICO.0000000000002589
doi:
Substances chimiques
Glucocorticoids
0
Immunosuppressive Agents
0
Ophthalmic Solutions
0
Cyclosporine
83HN0GTJ6D
Fluorometholone
SV0CSG527L
Banques de données
ClinicalTrials.gov
['NCT04376970']
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-732Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Jhanji V, Chan TCY, Li EYM, et al. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015;60:435–443.
Hillenkamp J, Sundmacher R, Reinhard T. Treatment of adenoviral keratoconjunctivitis. In: Reinhard T, ed. Cornea and External Eye Disease. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006:163–172.
Renard G. Adenoviral keratoconjunctivitis [in French]. J Fr Ophtalmol. 2010;33:586–592.
Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30:958–961.
Levinger E, Trivizki O, Shachar Y, et al. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:811–816.
Laibson PR, Dhiri S, Oconer J, et al. Corneal infiltrates in epidemic keratoconjunctivitis. Response to double-blind corticosteroid therapy. Arch Ophthalmol. 1970;84:36–40.
Trauzettel-Klosinski S, Sundmacher R, Wigand R. The effects of topical steroids in epidemic kerato-conjunctivitis (author's transl) [in German]. Klin Monatsbl Augenheilkd. 1980;176:899–906.
Romanowski EG, Yates KA, Gordon YJ. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea. 2002;21:289–291.
Holland EJ, Fingeret M, Mah FS. Use of topical steroids in conjunctivitis: a review of the evidence. Cornea. 2019;38:1062–1067.
Levinger E, Slomovic A, Sansanayudh W, et al. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010;29:638–640.
Muftuoglu IK, Akova YA, Gungor SG. Effect of 0.05% topical cyclosporine for the treatment of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis. Int J Ophthalmol. 2016;9:634–635.
Okumus S, Coskun E, Tatar MG, et al. Cyclosporine A 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol. 2012;12:42.
Asena L, Şıngar Özdemir E, Burcu A, et al. Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis. Eye (Lond). 2017;31:781–787.
Sundmacher R, Hillenkamp J, Reinhard T. Prospects for therapy and prevention of adenovirus keratoconjunctivitis [in German]. Ophthalmologe. 2001;98:991–1009.
Pinto RDP, Lira RPC, Abe RY, et al. Dexamethasone/Povidone eye drops versus artificial tears for treatment of presumed viral conjunctivitis: a randomized clinical trial. Curr Eye Res. 2015;40:870–877.
Maychuk DY, Vasil'eva OA, Russu LI, et al. Clinical and immunological comparisons of therapeutic regimens for corneal infiltrates secondary to adenoviral keratoconjunctivitis [in Russian]. Vestn Oftalmol. 2015;131:49–55.
Diao H, She Z, Cao D, et al. Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis. Adv Ther. 2012;29:645–653.
Pleyer U, Birnbaum F. Adenoviral keratoconjunctivitis [in German]. Ophthalmologe. 2015;112:459–469.
Reinhard T, Godehardt E, Pfahl HG, et al. Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. A pilot study [in German]. Ophthalmologe. 2000;97:764–768.
Vahlne A, Larsson PA, Horal P, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol. 1992;122:61–75.
Romanowski EG, Pless P, Yates KA, et al. Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea. 2005;24:86–91.
Böhringer D, Birnbaum F, Reinhard T. Cyclosporin A eyedrops for keratitis nummularis after adenovirus keratoconjunctivitis [in German]. Ophthalmologe. 2008;105:592–594.
Levy O, Labbé A, Borderie V, et al. Topical cyclosporine in ophthalmology: pharmacology and clinical indications. J Fr Ophtalmol. 2016;39:292–307.
Borel A, Albertini E, Bonnin N, et al. Une nouvelle ciclosporine A 1 % et 2 % : toxicité, tolérance et observance. J Fr Ophtalmol. 2009;32:175.
Chast F, Lemare F, Legeais JM, et al. Cyclosporine 2% eye drops preparation [in French]. J Fr Ophtalmol. 2004;27:267–276.
Hornecker MK, Weber SC, Piat MLB, et al. Cyclosporine eye drops: a 4-year retrospective study (2009–2013) [in French]. J Fr Ophtalmol. 2015;38:700–708.
Kuo IC. Adenoviral conjunctivitis in health care settings: why accurate diagnosis and infection control matter. JAMA Ophthalmol. 2017;135:905–906.
Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with sjögren syndrome. Medicine (Baltimore). 2015;94:551.
Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial. Ophthalmology. 2016;123:141–153.
Phulke S, Kaushik S, Kaur S, et al. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11:67–72.
Baratz KH, Hattenhauer MG. Indiscriminate use of corticosteroid-containing eyedrops. Mayo Clin Proc. 1999;74:362–366.
Mandapati JS, Metta AK. Intraocular pressure variation in patients on long-term corticosteroids. Indian Dermatol Online J. 2011;2:67–69.
Price MO, Price FW, Kruse FE, et al. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after Descemet membrane endothelial keratoplasty. Cornea. 2014;33:880–886.
Li Z, Chen W, Zhang Y, et al. Topical fluorometholone versus diclofenac sodium in cases with perennial allergic conjunctivitis. Eye Contact Lens. 2015;41:310–313.
Khurana S, Sharma N, Agarwal T, et al. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact. 2010;36:210–214.
Kwok AK, Lam DS, Ng JS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology. 1997;104:2112–2116.
Lam CS, Umi Kalthum MN, Norshamsiah MD, et al. Case series of children with steroid-Induced glaucoma. Malays Fam Physician. 2018;13:32–37.